The artificial heart transplant

In collaboration with the cardio-thoracic surgeons at Nantes University Hospital, Procope Medicals is developing a artificial heart transplant that can be implanted in people suffering from severe heart failure.

Treating severe heart failure thanks to our patented technology

Heart Failure is the inability of the heart to maintain, under normal conditions, the necessary blood flow for the body’s needs. It can affect the left and right sides of the heart, or both – this is called severe heart failure.

It is a progressive and irreversible illness.

Heart failure affects more than 26 million people worldwide. With around 160,000 patients per year, it is the 2nd highest cause of death. 97% of patients are waiting for a transplant and 65% of those patients will die within 12 months.

Procope Medicals is developing an artificial heart transplant / a totally artificial heart (TAH) that can be implanted in patients with severe heart failure. Its patented, original design achieves the performance of a natural heart.

A Completely Implantable Device

Optimized Design

Innovative Technology

2 Prosthesis Sizes

Prothèse cardiaque de cœur artificiel

There are numerous advantageous to the Procope artificial heart transplant...

Our pneumatic concept allows for the energy source – the battery and its charger, to function through the skin by using induction. Thus, no transcutaneous wires are required (cannulas, cables), which are often a source of recurrent infections in patients, post-operative complications and re-hospitalizations.
Since 2018, we have been collaborating with the surgeons at Nantes University Hospital. Alongside our engineers, they conceive of the ideal artificial heart transplant and we design it.
Our objective: lengthen the life expectancy of patients waiting for a transplant.

Our prosthesis fits all adults and doesn’t require transcutaneous connections to be recharged.

Contrary to artificial hearts that are currently on the market, the prosthesis developed by Procope Medicals does not require transcutaneous connections.

This means that the heart is not connected to an external battery by cables. It quickly recharges by being placed on the skin.
Reduces the risk of infections and other complications
Suitable for all adult patients
Provides patients with a better quality of life

Our technology timeline

2022
Prototype V0: Design, pump and distributor

Allow implantation in a maximum number of patient morphologies. Facilitate surgery and reduce the risk of complications. Ensure sufficient energy production and the pumping of blood under physiological conditions. Fit to the size of the prosthesis. Mimic the pulsality of a natural heart’s cardiac output.

2023
Prototype V1: Material, electronic controls

Ensure the biocompatibility necessary for the integration of the prosthesis into a patient’s body. Measure the physiological needs of the patient using sensors. Automatically configure the prosthesis’ operating parameters.

2024
Preclinical studies

2025
Prototype V2: Communication and power supply

Allow the prosthesis to communicate its operating parameters to an external monitoring system. Power the electronic components of the prosthesis and recharge it by induction.

2028
Clinical studies

Clinical studies before approval

2029
Availability on the market

Promote the Procope Medicals heart prosthesis to surgeons.